Yes. This is a game changer. Beyond being able to replace AVS, it allows one to “see” the underlying pathological contributors to a large proportion of “idiopathic” hypertension. This is another piece of evidence that should make clinicians rethink the pathogenesis and treatment of hypertension

Ok, we have a winner. Thanks. bsky.app/profile/matt...

I think Aliza Thompson is an unsung hero in this story for spearheading the albuminuria acceptance at FDA

journals.lww.com/cjasn/pages/...

#NephJC

And paper 3 from @cervantes-lily1.bsky.social

On adaptation of the Navigate Kidney intervention in @kireports.bsky.social

www.kireports.org/article/S246...

#KidneyWk

I like to lump patients with type IV collagen variants into 4 main categories that can help predict risk of progression and recommended treatment. #KidneyWk

This is amazing. Amazing. Fair play @hswapnil.bsky.social et al.

My vote for nephrology story of the year.

What about adjusting for follower count?